Report Overview

The EU Obesity Treatment Market was valued at USD 1.96 Billion in 2019 and is projected to reachUSD XX Billion by 2028, growing at aCAGR of XX% during the forecast period

Obesity is a complex disorder involving an excessive amount of body fat and thus increasing the risk of diseases and health diseases, high blood pressure, and diabetes. Obesity is diagnosed when the body mass index (BMI) is 30 or higher. It is caused by a number of factors such as an unhealthy diet, inactive lifestyle, consumption of alcohol, and lack of sleep. According to country estimates, more than 50% of both men and women in the EU were overweight, and roughly 23% of women and 20% of men were obese. In the EU, 1 in 3 eleven-year-olds were obese. Certain medications such as antidepressants, steroids, and beta-blockers as well as genes, as well as pregnancy can lead to obesity



Market Growth Drivers

The growing obese population, increasing number of bariatric surgeries, increasing incidence of lifestyle diseases, rising disposable income, and growing fast food industry are expected to drive the market growth. The EU obesity treatment market is propelled by a number of factors such as various government initiatives regarding overweight issues, technological advancements in the medical sector, commercial easy availability of weight management treatments. Many companies are engaged in the launch of new devices and medications with minimum side effects